​

iSpecimen Inc.

NasdaqCM:ISPC Stock Report

Market Cap: US$2.5m

iSpecimen (ISPC) Stock Overview

Operates marketplace that provides biospecimens to life science researchers worldwide. More details

ISPC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Earnings have declined by 14.5% per year over past 5 years

Does not have a meaningful market cap ($2M)

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the US market


ISPC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

INBS logo
Intelligent Bio Solutions
JO
Jolt_Communications
Community Contributor

The Future of Drug Testing? Fingerprint Tech Shows Serious Promise

Key Takeaways Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require pee cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.
View narrative
US$2.98
FV
43.0% undervalued intrinsic discount
59.20%
Revenue growth p.a.
10users have liked this narrative
0users have commented on this narrative
56users have followed this narrative
about 1 month ago author updated this narrative

iSpecimen Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for iSpecimen
Historical stock prices
Current Share PriceUS$0.96
52 Week HighUS$11.80
52 Week LowUS$0.85
Beta1.61
1 Month Change-23.81%
3 Month Change-20.00%
1 Year Change-82.80%
3 Year Change-97.97%
5 Year Changen/a
Change since IPO-99.33%

Recent News & Updates

Benign Growth For iSpecimen Inc. (NASDAQ:ISPC) Underpins Stock's 26% Plummet

Mar 05
Benign Growth For iSpecimen Inc. (NASDAQ:ISPC) Underpins Stock's 26% Plummet

Recent updates

Benign Growth For iSpecimen Inc. (NASDAQ:ISPC) Underpins Stock's 26% Plummet

Mar 05
Benign Growth For iSpecimen Inc. (NASDAQ:ISPC) Underpins Stock's 26% Plummet

iSpecimen Inc. (NASDAQ:ISPC) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

Jan 01
iSpecimen Inc. (NASDAQ:ISPC) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough

iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%

Sep 13
iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%

US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest Results

Aug 09
US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest Results

Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)

Jan 04
Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)

Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term

Aug 07
Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term

Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump

Apr 18
Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump

iSpecimen names finance chief Tracy Curley as interim CEO

Sep 22

iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's Estimates

Aug 10
iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's Estimates

iSpecimen GAAP EPS of -$0.30 misses by $0.02, revenue of $2.3M misses by $0.55M

Aug 04

iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price

Mar 31
iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price

Shareholder Returns

ISPCUS Healthcare ServicesUS Market
7D-2.0%0.4%1.8%
1Y-82.8%38.9%13.7%

Return vs Industry: ISPC underperformed the US Healthcare Services industry which returned 38.9% over the past year.

Return vs Market: ISPC underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is ISPC's price volatile compared to industry and market?
ISPC volatility
ISPC Average Weekly Movement11.7%
Healthcare Services Industry Average Movement10.5%
Market Average Movement7.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.7%

Stable Share Price: ISPC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ISPC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200924Robert Limispecimen.com

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.

iSpecimen Inc. Fundamentals Summary

How do iSpecimen's earnings and revenue compare to its market cap?
ISPC fundamental statistics
Market capUS$2.47m
Earnings (TTM)-US$11.25m
Revenue (TTM)US$8.06m
0.3x
P/S Ratio
-0.2x
P/E Ratio

Is ISPC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ISPC income statement (TTM)
RevenueUS$8.06m
Cost of RevenueUS$4.96m
Gross ProfitUS$3.10m
Other ExpensesUS$14.35m
Earnings-US$11.25m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-4.51
Gross Margin38.45%
Net Profit Margin-139.65%
Debt/Equity Ratio0%

How did ISPC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/07 21:51
End of Day Share Price 2025/07/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iSpecimen Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew HewittCraig-Hallum Capital Group LLC
Constantine DavidesD. Boral Capital LLC.
Ashok KumarThinkEquity LLC